DanCann Pharma A/S: The acquisition of CannGros ApS shows a prominent EBITDA of DKK 1.6 million for the annual 2021-report
COPENHAGEN, Denmark, 5 August 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the 2021 annual report for the Company’s subsidiary CannGros ApS (“CannGros”) shows positive results.In the beginning of July 2022 CannGros published the annual result for 2021. A positive EBITDA result of DKK 1.685 million means a fivefold increase from the 2020 result which is very satisfactory. In October 2021, DanCann Pharma acquired the wholesale company CannGros and at the same time took over import and distribution